Key result
Tumor mitotic rate ≥5/10 HPFs linked to ~168% higher disease-specific mortality versus acellular well-differentiated liposarcoma.
Why the study?
Criteria identifying low-grade dedifferentiation in WD/DDLPS are subjective and varying, and the value of mitotic rate in defining DDLPS and its association with survival are not confirmed.
Does mitotic rate distinguish dedifferentiated liposarcoma from well-differentiated liposarcoma in terms of disease-specific survival in patients with retroperitoneal WD/DDLPS?
Cohort (n=98)
No
Does mitotic rate distinguish dedifferentiated liposarcoma from well-differentiated liposarcoma in terms of disease-specific survival in patients with retroperitoneal WD/DDLPS?
Effect estimate: HR 2.68 (95% CI 1.07-6.71)
p-value: p=0.035
A mitotic rate of ≥5 mitoses/10 HPFs distinguishes dedifferentiated liposarcoma from well-differentiated liposarcoma and is associated with significantly worse disease-specific survival.
BACKGROUND: Subjective, varying criteria identify "low-grade" dedifferentiation in well-differentiated/dedifferentiated liposarcoma (WD/DDLPS). The value of mitotic rate (MR) in defining DDLPS is not confirmed. We studied all patients with the resection of their primary or first recurrence retroperitoneal WD/DDLPS at our institution to determine the value of MR in diagnosing DDLPS and if MR associates with patient survival. DESIGN: Ninety-eight patients with retroperitoneal WD/DDLPS operated at our institution from January 1, 1989 to December 31, 2013 were included. Cases were defined as acellular (AC) WDLPS, LS0-4 (tumors with non-lipogenic areas and MR 0-4/10HPFs) or LS5+(non-lipogenic areas, MR≥5/10 HPFs) and graded using the French system. Kaplan-Meier survival estimates with log-rank test and multivariate Cox (mCox) analyses were performed. RESULTS: Follow-up was available on all patients (median 9.3 y, range 0.02-23.16 y). Kaplan-Meier demonstrated a significant ( P =0.004) difference in disease-specific survival (DSS) among the 3 groups. mCox demonstrated no difference in DSS between the AC and LS0-4 groups (HR 1.51; 95% CI 0.57-3.99, P =0.412) but significantly lower DSS in the LS5+group compared with the AC group (HR 2.68; 95% CI 1.07-6.71, P =0.035). The difference in DSS was not significant between grade 2 and 3 tumors ( P =0.094). DSS between MR 5-19/10 HPFs and MR20+/10 HPFs subgroups was significant ( P =0.007) but by mCox did not reach significance (HR 2.47; 95% CI 0.96-6.35, P =0.060). CONCLUSION: This study confirms that MR distinguishes DDLPS from WDLPS with non-lipogenic areas, also known as cellular WDLPS. For consistency in diagnosis and research, only WD/DDLPS with≥5 mitoses/10 HPFs should be considered DDLPS.
No takes yet. Share an insight, caveat, or question.
Graham et al. (2023) conducted a cohort in Retroperitoneal well-differentiated/dedifferentiated liposarcoma (WD/DDLPS) (n=98). Mitotic rate ≥5/10 HPFs (LS5+) vs. Acellular WDLPS (AC) and MR 0-4/10 HPFs (LS0-4) was evaluated on Disease-specific survival (DSS) (HR 2.68, 95% CI 1.07-6.71, p=0.035). Tumors with a mitotic rate ≥5/10 HPFs had significantly lower disease-specific survival compared to acellular well-differentiated liposarcoma (HR 2.68; 95% CI 1.07-6.71, P=0.035).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: